-287), demonstrate the existence of ␣ IIb ␤ 3 agonist-specific activation states, explain the specificity for ligand binding and functional inhibition for some agonists, and predict the existence of agonist-specific final effectors and receptor activation mechanisms. The distinct non-reciprocal competition patterns observed at rest and after activation support the agonist-specific activation states and the existence of intrasubunit and intersubunit allosteric effects, previously proposed as the mechanism for ␣ IIb ␤ 3 transmembrane activation.
Integrin ␣ IIb ␤ 3 , a 230-kDa Ca 2ϩ -dependent heterodimeric protein peculiar to megakaryocytes and blood platelets, serves as the receptor for fibrinogen and other adhesive proteins upon platelet stimulation; also known as glycoprotein IIb/IIIa, it plays a crucial role in platelet adhesion to and spreading on the subendothelium, platelet aggregation, and clot retraction (1-3).
The genetic, biochemical, immunochemical, molecular dynamic, functional, pathological, and pharmacological characterization of ␣ IIb ␤ 3 is more advanced than similar knowledge about any other member of the integrin family. To acquire the receptor capacity (viz. recognition and binding of adhesive proteins), ␣ IIb ␤ 3 requires some induction mechanism to take place, which is physiologically linked to platelet activation by a variety of agonists and whose final step consists most probably of a change in the quaternary structure of the integrin (4) .
At present, the best molecular picture of ␣ IIb ␤ 3 in solution is that derived from protein chemical analysis (5-10); x-ray crystallography of the extracellular domain of ␣ v ␤ 3 (11) and the NMR structure of the epidermal growth factor-3 domain of ␤ 2 (12) ; mapping of antibody epitopes (13) , ligand-mimetic crosslinking sites (10, 14) , and natural and site-directed mutations (15, 16) ; electron microscopy (17) ; and molecular size and shape (18) . Integrins in solution appear in electron micrographs as a globular head with two legs, with the total length from tip to tip including the globular head being ϳ40 nm. The legs of ␣ IIb ␤ 3 are flexible and emerge from the same side of the head, with their tips either separated but never reaching a diametrical disposition (the head-free tail shapes), touching (the empty oval shapes) or overlapping (the bilobular shapes) each other, or fully folded on themselves and on the head (the filled globular shapes) (18) . This high degree of flexibility of the tails of the heterodimer, seen in electron micrographs and deduced from the crystallographic structure, accounts for the short rotational correlation times measured in Triton X-100 solutions by time-resolved fluorescence anisotropy. 1 Given its high segmental mobility, ␣ IIb ␤ 3 should adopt a large variety of shapes also in the membrane, where its lateral and rotational mobility has been measured (19, 20) . The integrin model that locates the subunit N-terminal domains at the globular head and the transmembrane and cytoplasmic domains at the tail ends was based on a combination of the morphological results and secondary structure prediction (21) and confirmed by the crystallographic structure. Electron micrographs of fibrinogen-␣ IIb ␤ 3 complexes suggest that the fibrinogen-binding site(s) is located at the integrin globular head (22) , and the cysteine-rich and proteinase-resistant core of ␤ 3 (␤ 3 -(423-622)) was tentatively localized in one of the heterodimer tails (23) . Finally, the sequences of the epitopes for monoclonal antibodies B1B5 (located at the C-terminal end of the ␣ IIb heavy chain) and LIBS2 (located within ␤ 3 -(602-690)) were also assigned to the ends of one of the tails (22, 24) . The latter sequence was thought to be joined by the Cys 406 -Cys 655 disulfide bond to the mid-region of ␤ 3 (not confirmed in the crystal structure), which was also joined to the N-terminal end by the Cys 5 -Cys 435 disulfide bond * This work was supported by Fondo de Investigaciones Sanitarias (FIS) Grants 98/032-01 and 2001/026 and Plan Nacional Grant SAF98-0110. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
‡ To whom correspondence should be addressed. Tel.: 34-1-561-9400; Fax: 34-1-564-2431; E-mail: J.Gonzalez-Rodriguez@iqfr.csic.es. (6) . Recently, the crystal structure of ␣ v ␤ 3 confirmed the metal ion-dependent adhesion site proposed earlier in the N-terminal region of ␤ 3 (MIDAS domain) (25) and the ␤ propeller with seven blades predicted in the N-terminal domain of the ␣ subunits (26) . However, discrepancies appeared in the disulfide arrangement of ␤ 3 proposed by protein chemical methods, x-ray diffraction, and NMR. Based on several pieces of evidence, a two-state allosteric model of integrin activation had been proposed (27) . The final effector(s) for the proposed allosteric transition has not been identified (4) , and information on the structure and disposition of the integrin in the membrane, both at rest and after activation, is lacking.
It has been known for some time that ADP-and thrombinactivated platelets (1), as well as platelets activated with some monoclonal antibodies (28) , differ in their specificity for the binding of adhesive proteins and monoclonal antibodies. Additionally, antibodies AP3 and Tab completely abolish ADPinduced platelet aggregation and secretion without impairing fibrinogen binding; however, thrombin-activated platelets neither aggregate nor bind fibrinogen in the presence of both antibodies (29) . Similarly, some anti-␣ IIb and anti-␤ 3 antibodies show agonist-dependent immunochemical inhibition of platelet aggregation in vitro (30) . Together, these observations suggest the existence of agonist-specific activated states of ␣ IIb ␤ 3 or different agonist-dependent membrane vicinities of the activated receptor. The existence of activated states differing in ligand affinity has been shown before for other integrins (31) (32) (33) (34) (35) , although we still lack information on the structural basis of these different activated states or receptor vicinities. On the other hand, "activated" forms of ␣ IIb ␤ 3 have been generated in cells, in whole platelets, and in solution by site-directed mutagenesis (36), interaction with RGD peptides (24) and monoclonal antibodies (28) , chemical reduction of disulfides (37), etc.; however, we lack information on the structural differences between the resting and activated forms.
Agonist-specific activation states of ␣ IIb ␤ 3 in the cell can be demonstrated by agonist-specific antibody recognition patterns. In this work, we have used a collection of monoclonal antibodies (mAbs) 2 directed against the calf-2 domain of ␣ IIb and the ␤A domain of ␤ 3 , whose epitopes have been located in their primary structures by protein chemical and immunochemical analyses (Refs. 7, 8, and 38 and this work). Competition among these antibodies for binding to whole platelets at rest and to ADP-, thrombin receptor activation peptide (TRAP)-, and arachidonic acid (AA)-activated platelets was quantified by bound-phase separation assays. The structural features deduced from the antibody competition patterns in resting platelets differ from those deduced from the patterns in ADP-, TRAP-, and AA-activated platelets, and the latter differ among themselves. We have compared these two-dimensional low resolution topographical maps and discussed them in relation to the structural and functional information currently available for integrin ␣ IIb ␤ 3 , and we have concluded that the maps are consistent with the existence of conformationally different agonist-dependent activation states of the integrin and with the bent structure both at rest and after activation and therefore inconsistent with the switchblade mechanism proposed for integrin activation (12) .
EXPERIMENTAL PROCEDURES

Materials
Isolation of Human Platelets-Blood samples were collected from healthy volunteers, and 9 volumes of blood were anticoagulated with 1 volume of 0.129 M trisodium citrate. Platelet-rich plasma was prepared by sedimentation of red and white blood cells at 150 ϫ g for 10 min. Washed platelets were prepared by gel filtration on a Sepharose 2B column equilibrated with Tyrode's buffer, 0.2% bovine serum albumin, and 5 mM glucose without calcium.
Isolation of ␣ IIb ␤ 3 and Its Subunits-Integrin ␣ IIb ␤ 3 was prepared from the membrane fraction of outdated human platelets as described (39) . The purified protein, free from salts and detergent, was freezedried and stored in liquid nitrogen. The ␣ IIb and ␤ 3 subunits were prepared from pure ␣ IIb ␤ 3 as described previously (39) .
Isolation and Labeling of Monoclonal Antibodies-The murine mAbs specific for ␤ 3 (P6, P23-7, P37, P40, P95-1, P95-2, and P97) and ␣ IIb (M␤1, M␤2, M␤ 3 , M␤4, M␤5, M3, M6, M9, M10, and M␣2), all of the IgG class, were prepared according to immunization and fusion protocols and screening assays described previously (38) . The antibodies were purified from ascites fluid after 50% saturated (NH 4 ) 2 SO 4 precipitation. The 50% saturated (NH 4 ) 2 SO 4 precipitate was subjected to affinity chromatography on protein A-Sepharose (Amersham Pharmacia Biotech) according to the manufacturer's instructions. The purification process was monitored by SDS-PAGE and enzyme immunoassay. Purified antibodies were labeled with fluorescein isothiocyanate (FITC) at pH 8.0 -9.0 and filtered through a Sephadex G-50 column (1 ϫ 40 cm) equilibrated with phosphate-buffered saline to separate the free dye. After clearing by centrifugation, the protein and bound dye in the FITC-antibody conjugates were measured spectrophotometrically at 280 and 495 nm, respectively, with the dye/ protein molar ratio being between 2 and 5. The labeled antibodies were monitored by enzyme immunoassay and SDS-PAGE, and their affinity for ␣ IIb ␤ 3 in solution was measured by enzyme immunoassay (40) . Concentrated solutions of antibodies were stored in liquid nitrogen.
Methods
Protein Analysis-Proteins (41) and free sulfhydryl groups and disulfide bonds (42) were determined as described previously. SDS-PAGE was carried out according to Laemmli (43) . For immunoblotting, gel electrophoresis bands were transferred to nitrocellulose or Immobilon by a standard procedure (44) . The goat anti-mouse IgG secondary antibody was affinity-purified and peroxidase-conjugated.
Proteolysis of the ␤ 3 Subunit and Isolation of the Heavy and Light Chains of ␣ IIb -The early 23-and 80-kDa tryptic fragments obtained by digestion of the ␤ 3 subunit were prepared and characterized as described previously (7) . The selective chemical reduction of the interchain disulfide bond of ␣ IIb and the isolation and analysis of the two chains were performed following earlier work (8) .
Assay of the Binding of Monoclonal Antibodies to ␣ IIb ␤ 3 in Whole Platelets-The affinity of the antibodies for ␣ IIb ␤ 3 in whole platelets and the number of binding sites per platelet were measured as follows. Increasing concentrations of the FITC-antibody conjugates were mixed with 5-10 l of platelet-rich plasma (1.5-3 ϫ 10 6 platelets) and brought to 50 l with Tyrode's buffer, 0.1% bovine serum albumin, and 1 mM CaCl 2 (equivalent to 5-10 nM ␣ IIb ␤ 3 ). After a 1-h incubation at 20°C, the mixtures were loaded on top of 20% sucrose in 400-l microcentrifuge tubes and centrifuged for 10 min at 5000 rpm. After, the tip of the tubes was cut and isolated using a razor blade, the supernatant was aspirated off the upper part, which was removed after thoroughly being washed and dried. The pellet was solubilized in 300 l of 0.1% SDS, and FITC-bound mAbs were measured in an SLM-AMINCO 8000 spectrofluorometer (excitation at 492 nm and emission at 530 nm). In experiments with activated platelets, 100 M ADP, 20 M TRAP, or 1 mM AA (final concentrations) was added with brief and gentle mixing (to avoid platelet aggregation) before antibody addition, and the samples were left resting for 1 h at room temperature. In the latter experiments, visual controls under the microscope were routinely done to check that the platelets had aggregated, but only after thorough mixing. Binding isotherms were constructed and fitted to a single binding site model to obtain the K d and the number of antibody-binding sites per platelet using Origin Version 5 (Microcal).
Competitive Binding Assays for Epitope Mapping of ␣ IIb ␤ 3 in Intact Platelets-FITC-labeled monoclonal antibody and competitive unlabeled antibody were added to 5-10 l of human platelet-rich plasma (adjusted to 3 ϫ 10 5 platelets/l) to reach final concentrations just below the K d (dissociation constant) for the labeled antibody and 5-10-fold greater than the K d for the unlabeled antibody. The mixture was brought to a final incubation volume of 50 l with Tyrode's buffer, 0.1% bovine serum albumin, and 1 mM CaCl 2 . Competition among antibodies for binding to human platelets was assayed by spectrofluorometric quantification of the platelet-bound FITC-labeled monoclonal antibodies after separation of the free and bound FITC-labeled antibodies by sedimentation as described above. Every antibody in the set was labeled and subjected to binding competition with the rest of the unlabeled antibodies.
Construction of Antigenic Maps in the Form of Venn Diagrams-
The results of the competition experiments in percent inhibition of binding of labeled antibodies by unlabeled antibodies were introduced in double-entry square tables: one entry for labeled (analysis) antibodies and the other for unlabeled (competition) antibodies. We considered paired antibodies to have competed sterically with each other when the percent inhibition for the pair in both entries was Ͼ75%. From the binary square matrix of data, which indicate the ability of paired antibodies to bind simultaneously or not to the antigen, the x-y coordinates for each antibody epitope were adjusted according to the experimental data to construct the two-dimensional map of the relative distribution of the antibody epitopes on the receptor surface. For this, we considered an average epitope area of 7 nm 2 and assigned the 0,0 coordinates to the epitope of the antibody that competed reciprocally with the highest number of antibodies in the set. The representation was done with Grapher Version 4 (Golden Software), with the position of non-overlapping epitopes being totally arbitrary.
Measurement of in Vitro Platelet Aggregation-The extent and rate of platelet aggregation in platelet-rich plasma, prepared as indicated above, were measured at 37°C under constant stirring in a spectrophotometer. Inhibition by anti-␣ IIb and anti-␤ 3 monoclonal antibodies of platelet aggregation induced by ADP, TRAP, and AA was expressed as a percentage of the decrease in the extent of aggregation with respect to the extent of aggregation of sample controls without antibody.
RESULTS
Further Localization of the Epitopes for Monoclonal Antibodies P23-7, P37, P40, P95-1, P95-2, and P97
Tryptic digestion of ␤ 3 in solution allows the selective and sequential cleavage of the Arg-X and Lys-X peptide bonds of (7). Using enzyme immunoassay and immunoelectroblotting, it was found that the epitope for P6 is resistant to degradation, and it was located in the 80-, 70-, and 50-kDa peptides. Given that it is exposed in whole platelets, its final location was limited to ␤ 3 -(303-692). The epitopes for P23-7 and P37 were found in the 23-kDa N-terminal fragment (␤ 3 -(1-216)), as described previously (7), where the epitopes for P40, P95-1, P95-2, and P97 were now also located. Of all these epitopes, that for P23-7 was the only one remaining in the 17-kDa fragment (␤ 3 -(1-150)) (Fig. 1A) . Given that these epitopes are resistant to reduction and alkylation and given that the 23-and 17-kDa fragments are not internally cleaved, as demonstrated by SDS-PAGE after full reduction and alkylation, the epitopes for P37, P40, P95-1, P95-2, and P97 were now located in ␤ 3 -(150 -216).
Localization of the Epitopes for Monoclonal Antibodies M␤2, M␤3, M␤4, M␤5, M9, and M10
Immunoelectroblotting and enzyme immunoassay detected the location of the M9 epitope in the heavy chain of ␣ IIb , whereas the epitopes for M␤2, M␤3, M␤4, and M␤5 were located in the light chain of ␣ IIb (Fig. 1B) . Given that the latter antibodies bind to whole platelets, their epitopes were located in the N terminus and extracellular domain of the light chain (␣ IIbL2 -(1-92)). On the other hand, the epitope for M10 was destroyed by selective reduction of the interchain disulfide bond ␣ IIbH Cys 826 -␣ IIbL2 Cys 9 of the ␣ IIb subunit, but not by denaturation; therefore, we located this epitope in the interchain region formed by the C terminus of ␣ IIbH and the N terminus of ␣ IIbL .
Binding of the Anti-␣ IIb and Anti-␤ 3 Antibodies to Whole Platelets
The K d values for the binding of the anti-␣ IIb and anti-␤ 3 FITC-mAb complexes in intact platelets at rest and after ADP, TRAP, and AA activation together with the number of mAbbinding sites per platelet and the epitope localization for each antibody are given in Table I . Examples of isotherms for binding for some anti-␣ IIb and anti-␤ 3 antibodies to resting and activated platelets are given in Fig. 2 . For a given mAb, the K d is generally higher for the isolated subunits (data not shown) and lower for the heterodimer in whole platelets, as expected, given that these antibodies were raised by animal immunization with isolated subunits or subunit fragments. The platelet determined in platelet homogenates by enzyme immunoassay was 98,382 Ϯ 11,818 and 113,612 Ϯ 11,800, respectively.
Competition between Antibodies for Binding to
␣ IIb ␤ 3 in Resting Platelets Table II shows four sets of antibodies competing reciprocally among themselves: P37, P95-1, P95-2, and P97; P95-1, P95-2, and M␤2; M␤1, M␤2, M␤4, M␤5, and M10; and M␤4, M␤5, M9, and M10. M␣2 competed with M10, whereas P6 and M3 did not compete with any of the antibodies. This suggests that the two subunits face each other along an interface formed by the epitope for M␤2 and by the epitopes for P95-1 and P95-2. The competition among the anti-␣ IIb antibodies outlines the interchain interface for this subunit perpendicular to the intersubunit interface.
Venn Diagram for ␣ IIb ␤ 3 in Resting Platelets
From the results of competition among antibodies for ␣ IIb ␤ 3 in resting platelets and taking into consideration the average size of the epitope for an IgG (7-8 nm 2 ), we constructed a Venn diagram showing the relative disposition on a plane surface of the epitopes for the reciprocally competing antibodies (Fig. 3A) . The intersubunit interface of the heterodimer, formed by the epitopes for M␤2, P95-1, and P95-2, corresponds to the extracellular domain of the light chain of ␣ IIb (␣ IIbL2 -(1-92) ) and the N terminus of the ␤ 3 subunit (␤ 3 -(150 -216) ). Outside the intersubunit interface, there is a second row of epitopes, one on each side. On the ␣ IIb side, the second row is formed by the epitopes for M␤1 (located at the N-terminal end of ␣ IIbL2 -(1-24)), M␤5 (situated in the extracellular domain of the light chain (␣ IIbL2 -(1-92)), M10 (which includes the interchain region comprising the interchain disulfide bond ␣ IIbH Cys 826 -␣ IIbL2 Cys 9 ), and M␣2 (␣ IIbH -(837-843), which overlaps with the epitope for M10 and is located at the C-terminal end of ␣ IIbH ). On the ␤ 3 side, the second row is formed by the epitopes for P37 and P97, both at the N terminus and in the ligandbinding domain of ␤ 3 (␤ 3 -(150 -216) ). Outside this second row of epitopes, a third row appears at the ␣ IIb side formed by the M␤4 epitope (which is located in the extracellular domain of ␣ IIbL2 - (Table III) , a new antibody competition pattern appeared, which was different from that in the resting state. The anti-␤ 3 antibodies P37, P95-1, P95-2, and P97 competed among themselves and with M␤2. M3, which in resting platelets did not compete with any of the antibodies, now competed with P37, P95-2, and P97 and with M␤1 and M␤2. mAb M␤1, M␤2, M␤4, M␤5, M9, and M10 competed among themselves. Finally, P6 and M␣2 did not compete with any of the antibodies.
TRAP-activated Platelets-In TRAP-activated platelets, the competition pattern observed (Table IV) follows the same lines as those for ADP-activated platelets, but with some remarkable differences. Thus, whereas P37, P95-1, P95-2, and P97 competed among themselves, M␤1, M␤2, M␤4, M␤5, M9, and M10 competed among themselves, too; P6 and M␣2 did not compete with any of these antibodies; M␤2 competed only with P95-2; and M3 competed with P37 and P95-1 and with M␤1, M␤2, and M␤4.
Arachidonic acid-activated Platelets-In AA-activated platelets, the competition pattern (Table V) follows some of the same lines seen above for ADP-and TRAP-activated platelets, the main difference being that none of the anti-␤ 3 antibodies competed with any of the anti-␣ IIb antibodies. M3 now competed only with M␤1, with which M␣2 also competed; and P6 behaved as before.
Venn Diagrams for ␣ IIb ␤ 3 in ADP-, TRAP-, and
AA-activated Platelets ADP-activated Platelets-When the two-dimensional antigenic map of ␣ IIb ␤ 3 in ADP-activated platelets (Fig. 3B ) is compared with the map in resting platelets, distinct features are immediately apparent. Now the five rows of epitopes found in the map of the resting state can be reduced to three; the epitope of M3 forms part of the subunit interface; and the epitopes seem to be crowded in a smaller area. At the ␣ IIb subunit side, the epitope for M3
(␣ IIbH -(849 -857)) forms part of the intersubunit interface, together with the epitope for M␤2 (␣ IIbL2 -(1-92)), which was already there at rest. At the ␤ 3 subunit side, the epitopes for P37 and P97 become part of the intersubunit interface, together with the epitopes for P95-1 and P95-2, which were already there at
FIG. 2. Binding isotherms of FITC-mAb conjugates.
A-D, binding of P37 to whole platelets at rest (data from five isotherms) and after activation by ADP (0.1 mM), TRAP (25 M), and AA (1 mM), respectively; E and F, binding of M3 (data from four isotherms) and M10 (data from two isotherms) to resting platelets, respectively.
rest. The centers of the epitopes for P6 and M␣2 are at a distance Ͼ3 nm from the centers of the epitopes for the rest of the antibodies; or alternatively, those epitopes are oriented so that that their occupation does not collide with that of the other epitopes. Outside the first row, at the ␣ IIb side, there is a second row of -(1-24) ), which also overlaps with the epitope for M3. (Table II) ; B, in ADP-activated platelets (Table III) ; C, in TRAP-activated platelets (Table IV) ; D, in AA-activated platelets (Table V) . The positions of non-overlapping epitopes are totally arbitrary, and the estimated diameter for each epitope is 3 nm.
TRAP-activated Platelets-The two-dimensional antigenic map for ␣ IIb ␤ 3 in TRAP-activated platelets (Fig. 3C) is almost the same as the ␣ IIb ␤ 3 map in ADP-activated platelets, with the following different features. At the ␣ IIb side, the intersubunit interface is still formed by the epitopes for M3 and M␤2, but now the epitope for M3 overlaps with that for P95-1, but not with those for P95-2 and P97, whereas the epitope for M␤2 overlaps only with P95-2; and at the second row of epitopes, M3 overlaps also with M␤4, i.e. the ␣ IIbH C-terminal end closes up with the extracellular domain of ␣ IIbL .
Arachidonic acid-activated Platelets-The main feature in the two-dimensional antigenic map of ␣ IIb ␤ 3 in AA-activated platelets (Fig. 3D) is that there is no overlap between any of the epitopes at the ␣ IIb side with any of those at the ␤ 3 side. The epitope for P6 remains Ͼ3 nm apart from the rest of the epitopes, and epitopes for P37, P95-1, P95-2, and P97 at the N terminus of ␤ 3 continue to overlap among themselves, as in the maps for resting and ADP-and TRAP-activated platelets. Finally, the epitope for M␤1 overlaps the epitopes for all the antibodies at the ␣ IIb side, and the epitopes for M3 and M␣2 
Non-reciprocal Antibody Binding Competitions
In Tables II-V for competition of antibody binding to ␣ IIb ␤ 3 in whole platelets, some antibody pairs did not show reciprocal binding competition, and they were considered as non-sterically competing antibodies. In Table II for resting platelets, only two pairs of antibodies showed non-reciprocal binding. Thus, the binding of M␤2, as the analysis antibody, was inhibited neither by P37 nor by P97; however, the binding of these two antibodies was inhibited when M␤2 was used as the competition antibody.
In Table III for ADP-activated platelets, eight pairs of antibodies showed non-reciprocal competition. Thus, both M␤1 and M␤4 competed with P37, but P37 competed with neither M␤1 nor M␤4. This happened with pairs M␤1/P97, M3/P95-1, M␤4/ P95-1, M10/M3, M3/M␤4, and M␣2/M␤4, with the last antibody in each pair being the competition antibody. Up to 14 pairs of antibodies showing non-reciprocal competition were found in TRAP-activated platelets (Table IV) : P95-1/M␤2, M␤1/P95-1, M␤1/P95-2, M␤1/P97, M␤2/P37, M␤2/M␣2, M3/P95-2, M3/P97, M␤4/P95-1, M␤4/P95-2, M␤4/P97, M9/M3, M10/M3, and M␣2/ M␤1. In AA-activated platelets, seven non-reciprocal competition pairs of antibodies were found (Table V) : M␤1/P95-2, M3/ P5-2, M3/P97, M9/M3, M␤2/P37, M␤2/P95-2, and M␤2/-M3. Finally, the non-reciprocally competing antibody pair M␤2/P37 was observed in resting and TRAP-and AA-activated platelets, but not in ADP-activated platelets; and 7 of the 14 non-reciprocally competing pairs in TRAP-activated platelets were observed in either ADP-or AA-activated platelets (Table VI) .
Immunoinhibition of in Vitro Platelet Aggregation by Anti-␣ IIb and Anti-␤ 3 Monoclonal Antibodies
The percent immunoinhibition of in vitro platelet aggregation induced by ADP, TRAP, and AA is shown in Table VII . The antibodies directed against the N terminus of ␤ 3 were the major inhibitors, although M6 was a potent inhibitor as well. Another noteworthy feature is the distinct degree of inhibition observed for some antibodies depending on the platelet activation agonist used, which confirms previous results. (303-350) ). Recently, the crystal structure of integrin ␣ v ␤ 3 , both isolated and in complex with an RGD peptide, was obtained (11) ; it shows a 135°V-shaped structure and confirms most of these features, in particular the proximity between the ␤A domain (␤ 3 -(109 -354)) and the calf-2 domain (␣ v -(739 -956)) (Fig. 4) , totally unexpected from the extended structures seen in electron micrographs. Table I ). The GRASP representation was done using the crystallographic coordinates given in Ref. 11. structural information drawn from the antigenic maps for resting and ADP-, TRAP-, and AA-activated ␣ IIb ␤ 3 in whole platelets. The antigenic map of ␣ IIb ␤ 3 in resting platelets found in this work allows us outline to the following structural features. First, the intersubunit interface observed is formed by a region of the ligand-binding domain of the ␤ 3 subunit (␤ 3 -(150 -216)) and the extracellular domain of the light chain (␣ IIbL2 -(1-92) ). Second, at one side of this intersubunit interface and perpendicular to it is the ␣ IIb interchain interface, made by the C-terminal domain of ␣ IIbH , including the interchain disulfide bond (Cys 826 -Cys 9 ), and the N terminus and extracellular domain of ␣ IIbL . Third, although ␣ IIbH -(837-843) (the epitope for M␣2) is close to the interchain disulfide bond in the C-terminal domain of ␣ IIbH , the very end of the heavy chain of ␣ IIb (␣ IIbH -(849 -857)), where the epitope for M3 is located, is either farther away, at a distance exceeding the average diameter of an epitope (Ͼ3 nm) or, alternatively, in a different orientation, which avoids the overlapping of M3 with the rest of the antibodies directed against the C-terminal domain of ␣ IIbH and the extracellular domain of ␣ IIbL . Thus, from the epitope map of ␣ IIb ␤ 3 in resting platelets, we can therefore conclude that the intersubunit interface observed between the C-terminal region of ␣ IIbH and the extracellular domain of ␣ IIbL (on one side) and part of the ligand-binding domain of ␤ 3 (on the other side) is in harmony with the proximity between these two regions suggested in the rudimentary map of ␣ IIb ␤ 3 in solution (9, 10) and in the crystal structure of ␣ v ␤ 3 (11) . However, this molecular picture does not agree with the ultrastructural model (22), unless we introduce in it the 135°bending of both subunits, as observed in the crystal structure of ␣ v ␤ 3 .
In activated platelets, ␣ IIb ␤ 3 presents characteristic structural features, some of which are common to the three agonists, and some of which are agonist-dependent. The main common structural features of the activated heterodimer are as follows. 1) The area occupied by the epitopes seems to be smaller in ADP-, TRAP-, and AA-activated platelets. However, although we observe an extended intersubunit interface in the maps of ADP-and TRAP-activated platelets compared with the map of resting platelets, no intersubunit interface is observed in the map of AA-activated platelets. In light of the ␣ v ␤ 3 V-shaped crystal structure, this can be interpreted as a closing up of the V-shape after ADP-and TRAP activation and as an opening up upon AA activation. 2) The interchain interface of ␣ IIb observed at rest is no longer discernible after activation. The epitope ␣ IIbH -(837-843) (M␣2) is oriented differently in ADP-and TRAP-activated ␣ IIb ␤ 3 , where M␣2 does not collide with any of the other antibodies, whereas in AA-activated ␣ IIb ␤ 3 , M␣2 collides with M␤1 (␣ IIbL -(1-24) ). 3) After activation with the three agonists, the C-terminal end of ␣ IIbH (the epitope for M3) gets close to the N-terminal end of ␣ IIbL (the epitope for M␤1), but it takes part of the intersubunit interface together with the ligand-binding domain in the N-terminal half of ␤ 3 , only after ADP and TRAP activation. In this respect, it is remarkable that, although the M3 epitope is always exposed, the epitope for PMI-1, an antibody directed against the very same end of the C terminus of ␣ IIbH , is fully exposed only after platelet aggregation and fibrinogen binding, after RGD peptide binding, or when the divalent ion concentration is Ͻ10 M (1). Similarly, selective removal of the C-terminal end of ␣ IIbH by ␣-chymotrypsin or neutrophil elastase seems to be related to the activation of platelets and fibrinogen binding (46) .
It is a characteristic feature of ␣ IIb ␤ 3 in ADP-activated platelets that all the epitopes in the ␤ 3 ligand-binding domain form part of the intersubunit interface and are closer to the extracellular domain of ␣ IIbL ; and in particular, those for P37, P97, and P95-2 are also close to the C-terminal end of ␣ IIbH . A characteristic feature of ␣ IIb ␤ 3 in TRAP-activated platelets is that the epitopes for P37, P95-1, and P97 move away from the extracellular domain of ␣ IIbL and that, although the epitope for P95-1 gets closer to the C-terminal end of ␣ IIbH , that for P97 moves away from it. Finally, a characteristic of ␣ IIb ␤ 3 in AAactivated platelets is that the ligand-binding domain of ␤ 3 moves away from both the C-terminal domain of ␣ IIbH and the extracellular domain of ␣ IIbL , whereas these two domains remain close to each other.
Some antibody pairs did not compete reciprocally; and therefore, these competitions have not been taken as steric competitions. However, they provide evidence for the existence of negative allosteric effects on antibody binding between two non-vicinal structural areas, both within the same subunit and between different subunits, as has been found before for ␣ IIb ␤ 3 and for other members of the integrin family (28, 47) . Similarly, a negative allosteric effect between the fibrinogen-and RGD peptide-binding sites has been found (48, 49) . It is worth noting that, for the set of anti-␣ IIb and anti-␤ 3 antibodies used here, the number of non-reciprocally competing antibody pairs found was much larger in activated than in resting platelets. The distinct non-reciprocally competing patterns observed for each agonist represent additional evidence for the existence of agonist-specific activation states of ␣ IIb ␤ 3 .
The present hypothesis on the activation of ␣ IIb ␤ 3 starts with the physiological agonists of platelet activation acting on their receptors at the platelet surface, initiating a series of inside-out signaling reactions and leading to the formation of the final effectors, still unresolved. These effectors interact with and modify the cytoplasmic and/or transmembrane domains of ␣ IIb ␤ 3 , which by transmembrane allosteric coupling would subsequently modify the extracellular domain, with the formation and/or exposure of the hidden ligand-binding sites, completing the receptor activation. So far, the most favored mechanism for transmembrane activation of ␣ IIb ␤ 3 has been the opening up of the intersubunit interface at the ligand-binding domains, as in the scissors model (4, 27) . Other mechanisms such as the dissociation, the piston movement, or the rotation along the membrane normal or the seesaw closing of the transmembrane segments could also lead to the opening up of the extracellular intersubunit interface (50) . Interpreted in the light of the crystal structure of ␣ v ␤ 3 , our results tell us that the ␤A domain of ␤ 3 moves closer to the calf-2 domain of ␣ IIb in the ADP-and TRAP-activated receptors, whereas the opposite movement takes place in the AA-activated receptor. Together with the relative change in orientation of the epitopes for M3 and M␣2, this points to a piston and rotation mechanism of the transmembrane segments along the membrane normal and argues against the recently made association of a switchblade mechanism with integrin activation (12) . If this is so, given the location of the binding sites for adhesion proteins in the ␤ propeller and ␤A domains and the 135°bend, one would expect the integrin legs to be oriented far from perpendicular to the membrane, to allow the binding sites to orient toward the extracellular space.
In this work, we have shown immunochemically the existence of agonist-specific activated states of ␣ IIb ␤ 3 , confirming functional evidence found before. Based on this, we predict agonist-specific final effectors and activation mechanisms. The non-steric competitions observed point to the existence of allosteric sites and support the proposed allosteric mechanisms of transmembrane activation. From the practical point of view, the agonist-specific activation states provide the possibility to distinguish between populations of activated platelets in circulation and to develop agonist-specific receptor inhibitors.
